#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Invasive Pulmonary Aspergillosis –⁠ A Common Accompanying Infection in Patients with Severe or Critical Course of COVID-19

Findings based on a literature review conducted and published in September 2020 show the occurrence of invasive pulmonary aspergillosis (IPA) in 19.6–33.3% of patients with a severe or critical course of COVID-19. The authors provide several important insights for clinical practice, including recommended management of therapy for these patients.
Source: Anti-Infectives 8. 2. 2021

News Therapy with Cyclosporine in the Context of the Coronavirus Pandemic

The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises concerns about possible risks associated with immunosuppressive treatment of autoimmune diseases. Specifically, does the use of cyclosporine increase the risk of infection, or does it act protectively?
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 4. 2021

News Safety Profile of Antiemetic Therapy in Patients Preparing for Hematopoietic Stem Cell Transplantation

An observational study conducted at a university clinic in Barcelona investigated the safety of the fixed combination of palonosetron and netupitant in patients preparing for hematopoietic stem cell transplantation.
Source: Antiemetic Therapy 15. 2. 2021

News Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting

Summary data from several studies were used by the authors of the following analysis to evaluate the efficacy of the intravenous and oral forms of the fixed combination NEPA (netupitant/fosnetupitant + palonosetron) administered with dexamethasone in preventing chemotherapy-induced vomiting based on cisplatin or anthracycline and cyclophosphamide (AC).
Source: Antiemetic Therapy 15. 2. 2021

News Do antiglaucoma drugs induce inflammation and irritation on the eye surface? Results of a 2-year randomized study

Eye drops for glaucoma treatment may contain preservatives responsible for eye irritation and possibly chronic inflammation. The study presented below is the first to compare the profile of inflammatory cytokines and eye irritation in patients using topical antiglaucoma drugs with and without preservatives.
Source: Treatment of Glaucoma 18. 2. 2021

News Antiglaucoma Eye Drops with Preservatives –⁠ Higher Likelihood of Glaucoma Surgery?

A recently published French study sought to answer the question of whether there is a connection between the presence of preservatives in antiglaucoma eye drops and the probability of undergoing glaucoma surgery.
Source: Treatment of Glaucoma 18. 2. 2021

News Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency

For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used functional tests as the main tool for monitoring the progression of lung disease. Now we are moving further. Quantitative CT examination is even more advantageous in terms of assessing clinical development.
Source: Deficiency of Alpha-1-Antitrypsin 18. 2. 2021

News Efficacy of Dabigatran on Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation

The direct thrombin inhibitor dabigatran has shown interesting efficacy in a smaller clinical study in patients with atrial fibrillation and a thrombus in the left atrial appendage. Chinese authors evaluated the results of anticoagulant therapy using transthoracic and transesophageal echocardiography.
Source: Anticoagulant Treatment 22. 2. 2021

News Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment

What are the outcomes of performing intravenous thrombolysis in patients with acute ischemic stroke after reversing the anticoagulant effect of dabigatran with idarucizumab? The answer is provided by a data analysis from real-world clinical practice in stroke centers, published by Czech authors.
Source: Anticoagulant Treatment 18. 2. 2021

News Do ACE Inhibitors Have a Protective Effect in People with COVID-19?

Although the COVID-19 pandemic has not lasted even a year, a number of studies have already been processed, examining the influence of various factors on the morbidity and mortality of patients. The presented meta-analysis investigated the influence of ACE inhibitors on the mortality of patients with this disease.
Source: ACE inhibitory 25. 2. 2021

News INFOGRAPHIC: Migraine Treatment Without Mistakes

A practical guide on how to proceed with the diagnosis of migraine, so that the treatment is effective and tailored to the patient.
Source: Migraine 22. 2. 2021

News Self-Administration of Romiplostim in Chronic Immune Thrombocytopenia: Analysis of 3 Studies

A post hoc analysis of 3 clinical studies showed that in adult patients with chronic immune thrombocytopenia (ITP), self-administration of romiplostim achieves comparable efficacy and safety as when the drug is administered by a healthcare professional.
Source: Immune Thrombocytopenia 23. 2. 2021

News Noonan Syndrome (Not Just) in the Pediatric Cardiologist's Office

Noonan Syndrome (NS) is a genetically determined disease associated with a high prevalence of (not just) congenital heart defects. When is it necessary to consider it in a cardiologist's office, where to refer the patient if suspected, and how to proceed if the diagnosis is confirmed?
Source: Growth Disorders 23. 2. 2021

News Recommended and Not Recommended Physical Activity for Individuals with Hemophilia

Physical activity is now considered a fundamental prerequisite for maintaining the health of individuals with hemophilia. The World Federation of Hemophilia (WFH) also recommends it to improve fitness and neuromuscular health. Numerous studies have shown that physical activity can help enhance the effectiveness of hemophilia treatment and prevent bleeding episodes. In older individuals, including those with hemophilia, a lack of physical activity increases the risk of developing diabetes, hypertension, dyslipidemia, obesity, and osteoporosis, along with subsequent fractures and complications associated with hemophilia.
Source: Hemophilia with Movement 25. 2. 2021

News Turoctocog Alfa Pegol and Its Impact on Health-Related Quality of Life

The presented work is based on the results of studies that evaluated how the administration of turoctocog alfa pegol affects the quality of life in individuals with severe hemophilia A. The obtained data also reflect the level of patient satisfaction with this treatment.
Source: Hemophilia with Movement 25. 2. 2021

1 103 104 105 106 107 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#